NEW ORLEANS, LA –

Exciting progress continues to emerge in the ongoing effort to advance Herpes Zoster vaccine research, particularly in co-administration of RSVPreF3 and RZV and how it could improve vaccine coverage and reduce the number of vaccination visits for adults older than 50 years of age.

Among the contributors and investigators to this work is Dr. Patrick Dennis at Touro Medical Center in New Orleans, LA. Serving as both a contributing author and principal investigator, Dr. Dennis played a key role in supporting the clinical execution of this Phase 3 program. His involvement reflects the critical role that experienced investigators and high-performing research sites play in bringing complex studies to life, ensuring not only rigorous data collection, but also meaningful contributions to broader scientific understanding.

The study highlights how participants who received both vaccines at the same time had immune responses similar to those who received the two vaccines one month apart. Efforts led by the GSK team, demonstrate how innovation remains central to the future of HZ vaccine development. Updating RSVPreF3 vaccine schedules to align with first doses of RZV could reduce the number of vaccination visits while being just as effective.

“Studies like this are critical to ensuring we stay ahead of constantly evolving vaccine coverage for patients,” said Rachel Hastings, Managing Partner at DelRicht Research. “By evaluating RSVPreF3 and RSV co-administration in real-world clinical settings, we’re not only strengthening our understanding of effectiveness and safety, we’re helping ensure that patients continue to have access to protection that reflects the current landscape of Shingles.”

The newly posted publication, “Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age,” was published in the Clinical Infectious Diseases Journal. As a leading forum for infectious diseases, CID provides a platform for sharing data that informs clinical practice and shapes future research priorities. Publications like this not only showcase scientific progress, but also reinforce the importance of collaboration across sponsors, research sites, and investigators worldwide.

DelRicht Research is proud to be part of this broader research community, one that is committed to advancing medicine through innovation, operational excellence, and patient-centered clinical trials. As Rachel Hastings mentioned, contributions from dedicated investigators like Dr. Dennis help ensure that research translates into real-world impact, ultimately improving outcomes for patients around the globe.

To explore the full findings, read the full publication here:
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag208/8665042